SURFACTANT PROTEIN D FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH LUNG INJURY
Surfactant protein D (SP-D) is a member of the collectin family of collagenous lectin domain-containing proteins that is expressed in epithelial cells of the lung. Described herein are methods and compositions for the treatment of disorders associated with lung injury, including methods and compositions for the treatment of bronchopulmonary disorder (BPD).
1 . A method for reducing the risk of developing bronchopulmonary dysplasia (BPD), comprising administering a composition comprising recombinant human SP-D (rhSP-D) and a pulmonary surfactant to a subject in need thereof in an amount effective to reduce the risk of developing BPD.
2 . The method of claim 1 , wherein the BPD is associated with lung injury from mechanical ventilation.
3 . The method of claim 1 , wherein the composition further comprises at least one protein selected from the group consisting of surfactant protein A (SP-A), surfactant protein B (SP-B), surfactant protein C (SP-C), and fragments and mimics thereof.
4 . The method of claim 1 , wherein the pulmonary surfactant is a synthetic surfactant protein.
5 . The method of claim 1 , wherein the dose of the rhSP-D is about 0.1 mg to about 10 mg/kg body weight of the subject.
6 . The method of claim 1 , wherein the dose of the rhSP-D is about 2 mg/kg body weight.
7 . The method of claim 6 , wherein the total dose of the composition is about 100 mg/kg body weight of the subject.
8 . The method of claim 1 , wherein the composition is administered intratracheally.
9 . The method of claim 1 , further comprising selecting a subject at risk for developing BPD prior to administering the composition to the subject.
10 . The method of claim 1 , wherein the subject is an infant.
11 . A method of reducing pulmonary injury associated with ventilation in a subject, comprising administering recombinant human surfactant protein D (rhSP-D) and a pulmonary surfactant to the subject in an amount effective to reduce pulmonary injury associated with the ventilation.
12 . The method of claim 11 , wherein the ventilation is mechanical ventilation.
13 . The method of claim 11 , wherein the composition further comprises at least one protein selected from the group consisting of surfactant protein A (SP-A), surfactant protein B (SP-B), surfactant protein C (SP-C), and fragments and mimics thereof
14 . The method of claim 11 , wherein the pulmonary surfactant is a synthetic surfactant protein.
15 . The method of claim 11 , wherein the dose of the rhSP-D is about 0.1 mg to about 10 mg/kg body weight of the subject.
16 . The method of claim 11 , wherein the dose of the rhSP-D is about 2 mg/kg body weight of the subject.
17 . The method of claim 16 , wherein the total dose of the composition is about 100 mg/kg body weight of the subject.
18 . The method of claim 11 , wherein the composition is introduced intratracheally.
19 . The method of claim 11 , further comprising selecting a subject at risk for developing BPD prior to administering the composition to the subject.
20 . The method of claim 11 , wherein the subject is an infant.